Skip to content

Effect and mechanism of Fury-style subcutaneous acupuncture combined with repetitive transcranial magnetic stimulation on weaning outcomes in patients with severe neurological disease

Effect and mechanism of Fury-style subcutaneous acupuncture combined with repetitive transcranial magnetic stimulation on weaning outcomes in patients with severe neurological disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117920
Enrollment
Unknown
Registered
2026-01-30
Start date
2025-02-20
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurocritical care unit

Interventions

Control Group A (rTMS Therapy):rTMS Therapy
Control Group A (FSN Therapy):FSN Therapy
Test Group (FSN Therapy + rTMS Therapy):FSN Therapy + rTMS Therapy

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. NCU patients: TBI, SAH, intracerebral hemorrhage (ICH), ischemic stroke, central nervous system infections (brain abscess, ventriculitis, meningitis, encephalitis, or brain tumor), etc.; 2. Age >=18 years; 3. Admitted to the ICU with a pre-intubation GCS =24 hours and an attempt at weaning (i.e., undergoing a weaning trial); 4. No severe complications, such as heart, brain, or kidney dysfunction, deep vein thrombosis, etc.; 5. Intact skin; 6. Informed consent signed by family members.

Exclusion criteria

Exclusion criteria: 1. Age < 18 years; 2. Presence of contraindications for FSN or rTMS (metal implants in the body, such as pacemakers, refractory epilepsy, recent severe injury or trauma, or pregnancy; skin surface infection, ulcer, or injury); 3. Spinal cord injury above T4, Guillain-Barré syndrome, motor neuron disease, myopathy, myasthenia gravis, or phrenic nerve paralysis; 4. Combined severe heart disease, liver cirrhosis, renal failure, severe systemic disease, or history of malignancy; 5. History of lung, chest, or abdominal diseases; 6. Refusal to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
duration of mechanical ventilation;QOL-MV questionnaire Score;ICU Length of Stay;TCM Syndrome Integral Scale Score;

Secondary

MeasureTime frame
Diaphragmatic Thickening Fraction, Abdominal Muscle Thickening Fraction;Airway Occlusion Pressure at 100 ms;StO2?THI;Amplitude of MEP?Latency of MEP?CMCT;Time of Inspiratory Effort, TIE;

Countries

China

Contacts

Public ContactYunlan Dai

Zhejiang Provincial People's Hospital

dyl6975@163.com+86 571 8766 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026